In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...
Read MoreCurrent stage-Stage III (Advanced) Posts on Medivizor
Evaluating a response-adapted treatment approach for pediatric patients with high-risk Hodgkin lymphoma
In a nutshell This study evaluated the outcomes of pediatric patients with high-risk Hodgkin lymphoma (HL) after response-adapted treatment. This study concluded that PET scanning during treatment can help adapt further treatments and improve outcomes for these patients. Some background For most pediatric patients with HL, outcomes after...
Read MoreReviewing the risk of neutropenia after first-line treatment for advanced Hodgkin lymphoma
In a nutshell This article reviewed the risk of patients with advanced Hodgkin lymphoma (HL) developing neutropenia after first-line treatment. This study concluded that this condition can be a serious complication for these patients. Some background The most commonly used frontline chemotherapy regimens for advanced HL are ABVD (doxorubicin,...
Read MoreSearching for children with advanced Hodgkin lymphoma to test a new chemoimmunotherapy combination regimen
In a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...
Read MoreEvaluating the impact of interim imaging on treatment outcomes for advanced cHL
In a nutshell This study investigated the impact of interim functional imaging (IFI) on the outcomes of treatment for advanced classical Hodgkin lymphoma (cHL). This study found that patients with positive scan results were more likely to disease progression. Some background ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the...
Read MoreLooking for patients with advanced stage Hodgkin lymphoma to test a treatment combination
In a nutshell This trial is examining the effectiveness of a new treatment combination for advanced Hodgkin’s lymphoma (HL). The main outcomes to be measured will be the number of patients who experience side effects and response to treatment. This study is being conducted in New York, New Jersey, and Ohio, the United States. The details The...
Read MoreEvaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma
In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreEvaluating long-term outcomes of R-CHOP for advanced follicular lymphoma
In a nutshell This study evaluated the long-term outcomes of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) treatment for previously untreated patients with advanced follicular lymphoma (FL). This study concluded that R-CHOP is effective in patients with newly diagnosed advanced FL. Some background FL is the second most...
Read MoreLong-term outcomes of radioimmunotherapy in patients with follicular lymphoma
In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...
Read MoreEvaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...
Read MoreHow safe and effective is R-CHOP as a first-line treatment for patients with FL in the long-term?
In a nutshell This study compared the safety and effectiveness of R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisone) to CHOP-RIT (CHOP followed by iodine-133-tositumomab, Bexxar) as a first-line treatment for follicular lymphoma (FL) patients. This study concluded that immunochemotherapy should remain the standard...
Read MoreIs R-CHOP chemotherapy an effective first-line treatment for patients with grade 3 follicular lymphoma?
In a nutshell This study analyzed the long-term outcomes of patients with grade 3 follicular lymphoma (FLG3) who received first-line R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The study concluded that this regimen is an effective first-line treatment for patients with FLG3, especially in those with less...
Read More
